Production (Stage)
BioSyent Inc.
RX.V
TSX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 27.48M | 25.56M | 25.36M | 24.97M | 24.36M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 27.48M | 25.56M | 25.36M | 24.97M | 24.36M |
| Cost of Revenue | 5.90M | 5.24M | 5.22M | 5.05M | 4.77M |
| Gross Profit | 21.58M | 20.32M | 20.14M | 19.92M | 19.59M |
| SG&A Expenses | 18.02M | 17.30M | 14.06M | 13.76M | 13.53M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 25.09M | 23.72M | 19.28M | 18.81M | 18.31M |
| Operating Income | 8.67M | 8.13M | 6.08M | 6.16M | 6.05M |
| Income Before Tax | 7.56M | 7.15M | 6.90M | 7.00M | 6.93M |
| Income Tax Expenses | 1.94M | 1.83M | 1.68M | 1.72M | 1.70M |
| Earnings from Continuing Operations | 5.62 | 5.31 | 5.23 | 5.29 | 5.24 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 5.62M | 5.31M | 5.23M | 5.29M | 5.24M |
| EBIT | 8.67M | 8.13M | 6.08M | 6.16M | 6.05M |
| EBITDA | 9.29M | 8.72M | 6.35M | 6.45M | 6.36M |
| EPS Basic | 0.49 | 0.46 | 0.45 | 0.45 | 0.44 |
| Normalized Basic EPS | 0.52 | 0.49 | 0.37 | 0.37 | 0.37 |
| EPS Diluted | 0.48 | 0.45 | 0.44 | 0.44 | 0.43 |
| Normalized Diluted EPS | 0.51 | 0.48 | 0.36 | 0.37 | 0.36 |
| Average Basic Shares Outstanding | 45.95M | 46.34M | 46.65M | 46.90M | 47.37M |
| Average Diluted Shares Outstanding | 46.84M | 47.20M | 47.50M | 47.73M | 48.21M |
| Dividend Per Share | 0.13 | 0.13 | 0.13 | 0.13 | 0.12 |
| Payout Ratio | 27.10% | 28.59% | 28.69% | 27.80% | 27.67% |